Responses
Regular and Young Investigator Award Abstracts
Immune Cell Types and Biology
1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
Compose a Response to This Article
Other responses
No responses have been published for this article.
